Abstract:Receptor activator of NF-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) are key regulators of bone metabolism under both normal and pathological conditions, including prostate cancer (PCa) bone metastases. However, little is known concerning the expression and function of these regulators in prostate tumor samples and PCa cells and their correlation with invasion and bone metastasis. In the present study, we determined the expression of RANK, RANKL and OPG in 3 human PCa cell lines and 40 PCa patient samples by immunohistochemistry and enzyme-linked immunosorbent assay (ELISA). As controls, samples from 20 patients with benign prostate hyperplasia (BPH) and normal prostate epithelial RWPE2 cells were also included in the analyses. The effects of soluble RANKL (sRANKL) and OPG as well as RANK knockdown on PCa invasion were examined in Transwell assays. Immunohistochemical staining detected little RANK, OPG and RANKL expression in hyperplasia prostate while the percentages of positivity were increased to 50, 45 and 52.5%, respectively, in prostate tumor tissues. OPG and sRANKL levels in the prostate tumor samples as measured by ELISA were ~10-fold that in the BPHs (P<0.01) and the levels were higher in aggressive tumors than non-aggressive ones (P<0.05). The sRANKL level in the serum of PCa patients was the same as that in the patients with BPH, yet the serum OPG levels correlated with the tissue levels (R2=0.620, P<0.01, which both showed a 10-fold increase in PCa over BPH (P<0.01) with higher levels in aggressive PCa than non-aggressive ones (P<0.05). Consistent with the tissue analyses, expression levels of RANK mRNA and protein were detected in multiple human PCa cell lines by RT-PCR and western blotting, respectively. The treatment of PCa cells with RANKL significantly increased the number of invaded cells (P<0.01), which was suppressed by the decoy receptor OPG. RANK siRNA transfection dramatically dampened the stimulatory effect of RANKL on PCa cell invasion. Our findings indicate that the expression of RANK, RANKL and OPG may be used as diagnostic markers to identify patients at high risk for aggressive PCa and that the effective suppression of PCa cell migration by OPG via the blockage of RANKL activity represents a potential therapeutic strategy for interfering with prostate tumor metastasis and progression to bone.

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

Targeting the RANKL/RANK/OPG Axis for Cancer Therapy

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

Expression Profile of Receptor Activator of Nuclear-Κb (RANK), RANK Ligand (RANKL) and Osteoprotegerin (OPG) in Breast Cancer.

The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies

Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

Receptor Activator of Nuclear Factor-Κb Ligand (rankl)/rank/osteoprotegerin System in Bone and Other Tissues (Review)

RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies

Receptor Activator Of Nuclear Factor-Kappa B Ligand (Rankl)/Rank/Osteoprotegerin System In Bone And Other Tissues

Abnormal Bone Remodeling Process Is Due To An Imbalance In The Receptor Activator Of Nuclear Factor-Kappa B Ligand (Rankl)/Osteoprotegerin (Opg) Axis In Patients With Solid Tumors Metastatic To The Skeleton

Differential Expression of the RANKL/RANK/OPG System is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer

[Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor]

Potential Role of the OPG/RANK/RANKL Axis in Prostate Cancer Invasion and Bone Metastasis

The Roadmap of RANKL/RANK Pathway in Cancer

RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model

Discovery of the RANKL/RANK/OPG system

Clinical prognostic significance and pro-metastatic activity of RANK/RANKL via the AKT pathway in endometrial cancer.

Targeting RANK/RANKL in the treatment of solid tumours and myeloma

RANKL and OPG Regulation on Bone Remodeling

Advances of RANKL/RANK Pathway in Tumorigenesis and Metastasis of Breast Cancer